CRTX vs. SGMO, ADVM, CHRS, SRRK, FMTX, OMCL, MDRX, HSTM, BLUE, and ATHA
Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Scholar Rock (SRRK), Forma Therapeutics (FMTX), Omnicell (OMCL), Veradigm (MDRX), HealthStream (HSTM), bluebird bio (BLUE), and Athira Pharma (ATHA).
Sangamo Therapeutics (NASDAQ:SGMO) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.
Sangamo Therapeutics currently has a consensus price target of $5.67, suggesting a potential upside of 886.88%. Given Cortexyme's higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Cortexyme.
Cortexyme has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
In the previous week, Sangamo Therapeutics had 4 more articles in the media than Cortexyme. MarketBeat recorded 4 mentions for Sangamo Therapeutics and 0 mentions for Cortexyme. Cortexyme's average media sentiment score of 1.09 beat Sangamo Therapeutics' score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 27.9% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cortexyme has a net margin of 0.00% compared to Cortexyme's net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -70.96% beat Cortexyme's return on equity.
Sangamo Therapeutics received 285 more outperform votes than Cortexyme when rated by MarketBeat users. However, 64.44% of users gave Cortexyme an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Summary
Cortexyme beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Cortexyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cortexyme Competitors List
Related Companies and Tools
